Platelet storage duration and its clinical and transfusion outcomes: A systematic review

Critical Care

Volumn 22, Issue 1, 2018, Pages

  Aubron, Cécile ^a,b   Flint, Andrew W J ^b,c   Ozier, Yves ^a   McQuilten, Zoe ^b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b MONASH UNIVERSITY   (Australia)

^c Royal Australian Navy   (Australia)

Author keywords

Allogeneic transfusion; Complication; Critically ill patients; Efficacy; Haematology patients; Platelet storage

Indexed keywords

BLEEDING; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; HUMAN; INFECTION RISK; LENGTH OF STAY; MORBIDITY; MORTALITY RATE; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SEPSIS; SYSTEMATIC REVIEW; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; CRITICAL ILLNESS; DRUG STORAGE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STANDARDS; THROMBOCYTE;

BLOOD PLATELETS; CRITICAL ILLNESS; DRUG STORAGE; HUMANS; PLATELET TRANSFUSION; TREATMENT OUTCOME;

EID: 85051088998     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-018-2114-x     Document Type: Review

References (37)

1. Estcourt LJ. Why has demand for platelet components increased? A review. Transfus Med. 2014;24(5):260-8.
2. Veihola M, Aroviita P, Linna M, Sintonen H, Kekomaki R. Variation of platelet production and discard rates in 17 blood centers representing 10 European countries from 2000 to 2002. Transfusion. 2006;46(6):991-5.
3. Bilgin YM, van de Watering LM, Versteegh MI, van Oers MH, Vamvakas EC, Brand A. Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion. 2011;51(12):2603-10.
4. Kaufman RM, Assmann SF, Triulzi DJ, Strauss RG, Ness P, Granger S, Slichter SJ. Transfusion-related adverse events in the platelet dose study. Transfusion. 2015;55(1):144-53.
5. Eder AF, Dy BA, Perez JM, Rambaud M, Benjamin RJ. The residual risk of transfusion-related acute lung injury at the American red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. Transfusion. 2013;53(7):1442-9.
6. Ning S, Barty R, Liu Y, Heddle NM, Rochwerg B, Arnold DM. Platelet transfusion practices in the intensive care unit: data from a large transfusion registry. Chest. 2016;150(3):516-23.
7. Vlaar AP, Hofstra JJ, Kulik W, van Lenthe H, Nieuwland R, Schultz MJ, Levi MM, Roelofs JJ, Tool AT, de Korte D, et al. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model. Blood. 2010;116(8):1360-8.
8. Cognasse F, Aloui C, Anh Nguyen K, Hamzeh-Cognasse H, Fagan J, Arthaud CA, Eyraud MA, Sebban M, Fromont E, Pozzetto B, et al. Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers. Transfusion. 2016;56(2):497-504.
9. Aslam R, Speck ER, Kim M, Freedman J, Semple JW. Transfusion-related immunomodulation by platelets is dependent on their expression of MHC class I molecules and is independent of white cells. Transfusion. 2008;48(9):1778-86.
10. Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R. The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage. Vox Sang. 2003;84(1):28-35.
11. Thon JN, Schubert P, Devine DV. Platelet storage lesion: a new understanding from a proteomic perspective. Transfus Med Rev. 2008;22(4):268-79.
12. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-14.
13. Aubron C, Flint AW, Ozier Y, McQuilten Z. Transfusion of stored platelets: balancing risks and product availability. Int J Clin Transfus Med. 2016;4:133-8.
14. Milford CE, Reade CM. Comprehensive review of platelet storage methods for use in the treatment of active hemorrhage. Transfusion. 2016;56(Suppl 2):S140-8.
15. Lozano MCJ. Platelet concentrates: balancing between efficacy and safety. Presse Med. 2016;45:e289-98.
16. Caram-Deelder C, Kreuger AL, Jacobse J, van der Bom JG, Middelburg RA. Effect of platelet storage time on platelet measurements: a systematic review and meta-analyses. Vox Sang. 2016;111(4):374-82.
17. Kreuger AL, Caram-Deelder C, Jacobse J, Kerkhoffs JL, van der Bom JG, Middelburg RA. Effect of storage time of platelet products on clinical outcomes after transfusion: a systematic review and meta-analyses. Vox Sang. 2017;112(4):291-300.
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
19. Jorgensen L, Paludan-Muller AS, Laursen DR, Savovic J, Boutron I, Sterne JA, Higgins JP, Hrobjartsson A. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Syst Rev. 2016;5:80.
20. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
21. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Spinella PC, Shulman I, Nelson J, Demetriades D. Impact of the duration of platelet storage in critically ill trauma patients. J Trauma. 2011;71(6):1766-73. discussion 1773-1764
22. Flint A, Aubron C, Bailey M, Bellomo R, Pilcher D, Cheng AC, Hegarty C, Reade MC, McQuilten Z. Duration of platelet storage and outcomes of critically ill patients. Transfusion. 2017;57(3):599-605.
23. Welsby IJ, Lockhart E, Phillips-Bute B, Campbell ML, Mathew JP, Newman MF, Peterson E, Milano CA. Mark Stafford-smith for members of the cardiothoracic anesthesiology research endeavors DoADUMC: Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion. 2010;50(11):2311-7.
24. Juffermans NP, Prins DJ, Vlaar AP, Nieuwland R, Binnekade JM. Transfusion-related risk of secondary bacterial infections in sepsis patients: a retrospective cohort study. Shock. 2011;35(4):355-9.
25. Juffermans NP, Vlaar AP, Prins DJ, Goslings JC, Binnekade JM. The age of red blood cells is associated with bacterial infections in critically ill trauma patients. Blood Transfus. 2012;10(3):290-5.
26. MacLennan S, Harding K, Llewelyn C, Choo L, Bakrania L, Massey E, Stanworth S, Pendry K, Williamson LM. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets. Transfusion. 2015;55(8):1856-65. quiz 1855
27. Diedrich B, Ringden O, Watz E, Shanwell A. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients. Vox Sang. 2009;97(3):254-9.
28. Dijkstra-Tiekstra MJ, Pietersz RN, Hendriks EC, Reesink HW, Huijgens PC. In vivo PLT increments after transfusions of WBC-reduced PLT concentrates stored for up to 7 days. Transfusion. 2004;44(3):330-6.
29. Dijkstra-Tiekstra MJ, van de Watering LM, Rondeel JM, Slomp J, de Wildt-Eggen J. Implementation of a new platelet pooling system for platelet concentrates led to a higher corrected count increment after transfusion: a comparative observational study of platelet concentrates before and after implementation. Transfus Med. 2014;24(2):99-104.
30. Kaplan A, Lindgren B, Marschner S, Aznar M, Zalba S, Sanchez P, Ayape ML, Olavarria E, Antelo ML. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days. Transfus Apher Sci. 2016;54(2):248-52.
31. Akkok CA, Brinch L, Lauritzsen GF, Solheim BG, Kjeldsen-Kragh J. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sang. 2007;93(1):42-8.
32. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209-17.
33. Heuft HG, Goudeva L, Krauter J, Peest D, Buchholz S, Tiede A. Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation. Vox Sang. 2013;105(1):18-27.
34. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, Granger S, Slichter SJ. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood. 2012;119(23):5553-62.
35. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101(6):2426-33.
36. Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C, Meyer-Monard S, Halter J, Tichelli A, Gratwohl A. Patient and product factors affecting platelet transfusion results. Transfusion. 2008;48(4):681-7.
37. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600-13.